Por favor, use este identificador para citar o enlazar este ítem:
https://hdl.handle.net/11000/31097
Registro completo de metadatos
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Barrajón-Catalán, Enrique | - |
dc.contributor.author | Menéndez-Gutierrez, María P. | - |
dc.contributor.author | Falcó, Alberto | - |
dc.contributor.author | Carrato, Alfredo | - |
dc.contributor.author | Saceda, Miguel | - |
dc.contributor.author | Micol, Vicente | - |
dc.contributor.other | Departamentos de la UMH::Bioquímica y Biología Molecular | es_ES |
dc.date.accessioned | 2024-02-05T17:55:28Z | - |
dc.date.available | 2024-02-05T17:55:28Z | - |
dc.date.created | 2010-04-28 | - |
dc.identifier.citation | Cancer Letters, Volume 290, Issue 2, 2010, Pages 192-203 | es_ES |
dc.identifier.issn | 1872-7980 | - |
dc.identifier.issn | 0304-3835 | - |
dc.identifier.uri | https://hdl.handle.net/11000/31097 | - |
dc.description.abstract | Trastuzumab (Herceptin™) targets the human epidermal growth factor receptor 2 (HER2), which is overexpressed in 20–30% of breast and ovarian cancers carrying a bad prognosis. Our purpose was to target HER2-overexpressing human breast cancer cells with pegylated immunoliposomes bearing trastuzumab and containing melittin, which has recently shown anticancer properties. Using a panel of human breast cancer cells with different HER2 expression levels, these immunoliposomes decreased cancer cells viability in a dose–response manner and in correlation to their level of HER2 expression. Specific binding of the immunoliposomes to SKBr3 breast cancer cells was shown by ImageStream-based analysis. The morphological changes observed in the treated cells suggested a cytolytic process. This preclinical approach may suppose an effective strategy for the treatment of HER2-overexpressing tumors, and can support the development of an early phases I–II clinical trial. Trastuzumab resistant breast cancer cells (JIMT-1), can also be targeted using this approach. | es_ES |
dc.format | application/pdf | es_ES |
dc.format.extent | 12 | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier | es_ES |
dc.rights | info:eu-repo/semantics/closedAccess | es_ES |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Trastuzumab | es_ES |
dc.subject | Immunoliposomes | es_ES |
dc.subject | MelittinCell | es_ES |
dc.subject | Cell lysisHER2 | es_ES |
dc.subject | HER2 | es_ES |
dc.subject | Anticancer therapy | es_ES |
dc.subject | Breast cancer cells | es_ES |
dc.subject.other | CDU::5 - Ciencias puras y naturales::57 - Biología | es_ES |
dc.title | Selective death of human breast cancer cells by lytic immunoliposomes: Correlation with their HER2 expression level | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.relation.publisherversion | https://doi.org/10.1016/j.canlet.2009.09.010 | es_ES |
![no-thumbnail](/image/nothumb.jpg)
10_3_Cancer letters 4.864.pdf
1,45 MB
Adobe PDF
Compartir:
La licencia se describe como: Atribución-NonComercial-NoDerivada 4.0 Internacional.